Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.4607 +0.0107 (+2.38%)
Streaming Delayed Price Updated: 10:23 AM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 113,499
Open 0.4400
Bid (Size) 0.4568 (1)
Ask (Size) 0.4647 (5)
Prev. Close 0.4500
Today's Range 0.4350 - 0.4651
52wk Range 0.4901 - 109.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Top movers in Friday's pre-market session
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill

Performance

YTD
-92.4%
-92.4%
1 Month
-50.2%
-50.2%
3 Month
-72.4%
-72.4%
6 Month
-97.3%
-97.3%
1 Year
-99.6%
-99.6%

More News

Read More
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Thursday's session: top gainers and losers
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session.
Via Chartmill
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are gapping on Thursday?
Via Chartmill
Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
Top movers in Thursday's pre-market session
Via Chartmill
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish
Via Stocktwits

Frequently Asked Questions

Is CERo Therapeutics Holdings, Inc. - Common Stock publicly traded?
Yes, CERo Therapeutics Holdings, Inc. - Common Stock is publicly traded.
What exchange does CERo Therapeutics Holdings, Inc. - Common Stock trade on?
CERo Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock?
The ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock is CERO on the Nasdaq Stock Market
What is the current price of CERo Therapeutics Holdings, Inc. - Common Stock?
The current price of CERo Therapeutics Holdings, Inc. - Common Stock is 0.4607
When was CERo Therapeutics Holdings, Inc. - Common Stock last traded?
The last trade of CERo Therapeutics Holdings, Inc. - Common Stock was at 06/03/25 10:23 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.